Imaging Blood-Brain Barrier Permeability with Anti-Amyloid Immunotherapy for Alzheimer's Disease

Study Name	Imaging blood-brain barrier permeability with anti-amyloid immunotherapy for Alzheimer’s disease
Principal Investigator(s)	Emilie Reas, Ph.D.
Required Diagnosis	Cognitively normal, MCI, or early AD; eligible for lecanemab or donanemab
Age	60+
Length & Procedures	Pre-screening: Telephone interview to discuss study procedures and to schedule research visits Visit 1* (<2 hours; East campus office building (ECOB), 9444 Medical Center Dr): Study consent Blood draw to confirm safety for contrast MRI Cognitive testing Visit 2: (1.5 hours; Altman Clinical & Translational Research Institute (ACTRI), 9452 Medical Center Dr): 45-minute MRI scan with contrast Health and lifestyle questionnaire Saliva sample for genetic testing $100 study compensation * If recent GFR is available (<6 weeks of MRI), visit 1 can be skipped, and blood draw and cognitive testing can be conducted at visit 2. Follow-up: Visit 1 & 2 repeated at 12-months and upon ARIA detection
Lumbar Puncture	No
MRI	Yes w/ contrast
Amyloid PET	No
Tau PET	No
Compensation	$100
Contact	Charlotte Rivera, c8rivera@health.ucsd.edu (English) Kassandra Portillo, kportillo@health.ucsd.edu (Spanish/English)
More Information	Study Flyer